Advertisement

RhoC GTPase in Cancer Progression and Metastasis

Chapter

Abstract

RhoC GTPase is more than 90% homologous to RhoA GTPase and was thought to have functions redundant to RhoA. Evidence over the years has demonstrated that despite their high degree of homology, RhoA and RhoC have distinct functions within the cell. Specifically, RhoC GTPase appears to be associated with particularly aggressive cancers and metastasis leading to increased migration and invasion. Unlike RhoA, expression and activation of RhoC appears to be dispensable for normal development and function. These attributes make RhoC a particularly attractive prognostic marker and potential antimetastatic target.

Keywords

LNCaP Cell Inflammatory Breast Cancer Inflammatory Breast Cancer Cell Inflammatory Breast Cancer Cell Line Inflammatory Breast Cancer Tumor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Adamson P, Marshall CJ, Hall A, Tilbrook PA (1992) Post-translational modifications of p21rho proteins. J Biol Chem 267:20033–20038.PubMedGoogle Scholar
  2. Arthur WT, Burridge K (2001) RhoA inactivation by p190RhoGAP regulates cell spreading and migration by promoting membrane protrusion and polarity. Mol Biol Cell 12:2711–2720.PubMedGoogle Scholar
  3. Avraham H (1990) Rho gene amplification and malignant transformation. Biochem Biophys Res Commun 168:114–124.CrossRefGoogle Scholar
  4. Billuart P, Winter CG, Maresh A, Zhao X, Luo L (2001) Regulating axon branch stability: the role of p190 RhoGAP in repressing a retraction signaling pathway. Cell 107:195–207.CrossRefPubMedGoogle Scholar
  5. Bishop AL, Hall A (2000) Rho GTPases and their effector proteins. Biochem J 348(Pt 2):241–255.CrossRefPubMedGoogle Scholar
  6. Brown R, Marshall CJ, Pennie SG, Hall A (1984) Mechanism of activation of an N-ras gene in the human fibrosarcoma cell line HT1080. EMBO J 3:1321–1326.PubMedGoogle Scholar
  7. Capon DJ, Seeburg PH, McGrath JP, et al (1983) Activation of Ki-ras2 gene in human colon and lung carcinomas by two different point mutations. Nature 304:507–513.CrossRefPubMedGoogle Scholar
  8. Carr KM, Bittner M, Trent JM (2003) Gene-expression profiling in human cutaneous melanoma. Oncogene 22:3076–3080.CrossRefPubMedGoogle Scholar
  9. Clark EA, Golub TR, Lander ES, Hynes RO (2000) Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406:532–535.CrossRefPubMedGoogle Scholar
  10. Crnogorac-Jurcevic T, Efthimiou E, Nielsen T, et al (2002) Expression profiling of microdissected pancreatic adenocarcinomas. Oncogene 21:4587–4594.CrossRefPubMedGoogle Scholar
  11. del Peso L, Hernandez-Alcoceba R, Embade N, et al (1997) Rho proteins induce metastatic properties in vivo. Oncogene 15:3047–3057.CrossRefPubMedGoogle Scholar
  12. Dias S, Cerione RA (2008) X-ray crystal sturctures reveal two actived states for RhoC. Biochemistry 46:6547–6558.CrossRefGoogle Scholar
  13. Du W, Lebowitz PF, Prendergast GC (1999) Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. Mol. Cell Biol 19:1831–1840.Google Scholar
  14. Feramisco JR, Gross M, Kamata T, Rosenberg M, Sweet RW (1984) Microinjection of the oncogene form of the human H-ras (T-24) protein results in rapid proliferation of quiescent cells. Cell 38:109–117.CrossRefPubMedGoogle Scholar
  15. Fritz G, Just I, Kaina B (1999) Rho GTPases are over-expressed in human tumors. Int J Cancer 81:682–687.CrossRefPubMedGoogle Scholar
  16. Groh K, Lin M, van Golen CM, van Golen KL (2006) The Rho GTPases and angiogenesis. In: Zubar R (ed) New angogenesis research. Nova Biomedical Books, New York, pp. 19–42.Google Scholar
  17. Hakem A, Sanchez-Sweatman O, You-Ten A, et al (2005) RhoC is dispensable for embryogenesis and tumor initiation but essential for metastasis. Genes Dev 19:1974–1979.CrossRefPubMedGoogle Scholar
  18. Hall A (1990) The cellular functions of small GTP-binding proteins. Science 249:635–640.CrossRefPubMedGoogle Scholar
  19. Hall A (1998) Rho GTPases and the actin cytoskeleton. Science 279:509–514.CrossRefPubMedGoogle Scholar
  20. Hall A, Marshall CJ, Spurr NK, Weiss RA (1983) Identification of transforming gene in two human sarcoma cell lines as a new member of the ras gene family located on chromosome 1. Nature 303:396–400.CrossRefPubMedGoogle Scholar
  21. Hall C, Dai J, van Golen KL, Keller ET, Long M (2006) Type I colagen receptor (alpha2 beta1) signaling promotes the growth of human prostate cancer cells within the bone. Cancer Res 66:8648–8654.CrossRefPubMedGoogle Scholar
  22. Hall C, Shein D, Dubyk C, Riesenberger T, Keller ET, van Golen KL (2008) Type I Collagen receptor (alpha2beta3) signaling promotes prostate cancer cell invasion through RhoC GTPase. Neoplasia In Press.Google Scholar
  23. Hall C, Dubyk CW, Riesenberger TA, Shein D, Keller ET, van Golen KL Neoplasia 10(8):797–803.PubMedGoogle Scholar
  24. Haskell MD, Slack JK, Parsons JT, Parsons SJ (2001) c-Src tyrosine phosphorylation of epidermal growth factor receptor, P190 RhoGAP, and focal adhesion kinase regulates diverse cellular processes. Chem Rev 101:2425–2440.CrossRefPubMedGoogle Scholar
  25. Horiuchi A, Imai T, Wang C, et al (2003) Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma. Lab Invest 83:861–870.PubMedGoogle Scholar
  26. Ihara K, Muraguchi S, Kato M, et al (1998) Crystal structure of human RhoA in a dominantly active form complexed with a GTP analoge. J Biol Chem 273:9656–9666.CrossRefPubMedGoogle Scholar
  27. Imamura F, Mukai M, Ayaki M, et al (1999) Involvement of small GTPases Rho and Rac in the invasion of rat ascites hepatoma cells. Clin Exp Metastasis 17:141–148.CrossRefPubMedGoogle Scholar
  28. Jaiyesimi IA, Buzdar AU, Hortobagyi G (1992) Inflammatory breast cancer: a review. J Clin Oncol 10:1014–1024.PubMedGoogle Scholar
  29. Kamai T, Tsujii T, Arai K, et al (2003) Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res 9:2632–2641.PubMedGoogle Scholar
  30. Kirschmeier PT, Whyte D, Wilson O, Bishop WR, Pai JK (2001) In vivo prenylation analysis of Ras and Rho proteins. Methods Enzymol 332:115–127.CrossRefPubMedGoogle Scholar
  31. Kleer CG, van Golen KL, Merajver SD (2000) Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res 2:423–429.CrossRefPubMedGoogle Scholar
  32. Kleer CG, van Golen KL, Zhang Y, Wu ZF, Rubin MA, Merajver SD (2002a) Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability. Am J Pathol 160:579–584.PubMedGoogle Scholar
  33. Kleer CG, Zhang Y, Pan Q, et al (2004a) WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer. Breast Cancer Res Treat 6:110–115. Ref Type: GenericGoogle Scholar
  34. Kleer CG, Zhang Y, Pan Q, Merajver SD (2004b) WISP3 (CCN6) is a secreted tumor-suppressor protein that modulates IGF signaling in inflammatory breast cancer. Neoplasia 6:179–185.CrossRefPubMedGoogle Scholar
  35. Kleer CG, Zhang Y, Pan Q, et al (2002b) WISP3 is a novel tumor suppressor gene of inflammatory breast cancer. Oncogene 21:3172–3180.CrossRefPubMedGoogle Scholar
  36. Klein WM, Hruban RH, Klein-Szanto AJ, Wilentz RE (2002) Direct correlation between proliferative activity and dysplasia in pancreatic intraepithelial neoplasia (PanIN): additional evidence for a recently proposed model of progression. Mod Pathol 15:441–447.CrossRefPubMedGoogle Scholar
  37. Kondo T, Sentani K, Oue N, Yoshida K, Nakayama H, Yasui W (2004) Expression of RHOC is associated with metastasis of gastric carcinomas. Pathobiology 71:19–25.CrossRefPubMedGoogle Scholar
  38. Lebowitz PF, Casey PJ, Prendergast GC, Thissen JA (1997) Farnesyltransferase inhibitors alter the prenylation and growth- stimulating function of RhoB. J Biol Chem 272:15591–15594.CrossRefPubMedGoogle Scholar
  39. Lebowitz PF, Davide JP, Prendergast GC (1995) Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity. Mol Cell Biol 15:6613–6622.PubMedGoogle Scholar
  40. Lin M, DiVito MM, Merajver S, Boyanapalli M, van Golen KL (2005) Regulation of pancreatic cancer cell migration and invasion RhoC GTPase and caveolin-1. Mol Cancer 4:21.CrossRefPubMedGoogle Scholar
  41. Lin M, van Golen KL (2004) Rho-regulatory proteins in breast cancer cell motility and invasion. Breast Cancer Res. Treat. (2004) 84:49–60.CrossRefGoogle Scholar
  42. Logsdon CD, Simeone DM, Binkley C, et al (2003) Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res 63:2649–2657.PubMedGoogle Scholar
  43. Longenecker K, Read P, Somlyo A, Nakamoto R, Derewenda Z (2003) Structure of a constitutively activated RhoA mutant (Q63L) at a 1.55 A resolution. Acta Crystalllogr D Biol Crystallogr 59:876–880.CrossRefGoogle Scholar
  44. Marionnet C, Lalou C, Mollier K, et al (2003) Differential molecular profiling between skin carcinomas reveals four newly reported genes potentially implicated in squamous cell carcinoma development. Oncogene 22:3500–3505.CrossRefPubMedGoogle Scholar
  45. McGrath JP, Capon DJ, Smith DH, et al (1983). Structure and organization of the human Ki-ras proto-oncogene and a related processed pseudogene. Nature 304:501–506.CrossRefPubMedGoogle Scholar
  46. Moorman JP, Luu D, Wickham J, Bobak DA, Hahn CS (1999). A balance of signaling by Rho family small GTPases RhoA, Rac1 and Cdc42 coordinates cytoskeletal morphology but not cell survival. Oncogene 18:47–57.CrossRefPubMedGoogle Scholar
  47. Moscow JA, He R, Gnarra JR, et al (1994) Examination of human tumors for rhoA mutations. Oncogene 9:189–194.PubMedGoogle Scholar
  48. Pille JY, Denoyelle C, Varet J, et al (2005) Anti-RhoA and anti-RhoC siRNAs inhibit the proliferation and invasiveness of MDA-MB-231 breast cancer cells in vitro and in vivo. Mol Ther 11:267–274.CrossRefPubMedGoogle Scholar
  49. Pille JY, Li H, Bertand J, et al (2008) Intravenous delivery of anti-RhoA small interferring RNA loaded in nonoparticles of chitosan in mice: Safety and efficacy in xenografted aggressive breast cancer. Hum Mol Genet 17:1019–1026.Google Scholar
  50. Prendergast GC, Khosravi-Far R, Solski PA, Kurzawa H, Lebowitz PF, Der CJ (1995) Critical role of Rho in cell transformation by oncogenic Ras. Oncogene 10:2289–2296.PubMedGoogle Scholar
  51. Ridley AJ, Hall A (1992a) Distinct patterns of actin organization regulated by the small GTP- binding proteins Rac and Rho. Cold Spring Harb Symp Quant Biol 57:661–671.PubMedGoogle Scholar
  52. Ridley AJ, Hall A (1992b) The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 70:389–399.CrossRefPubMedGoogle Scholar
  53. Ridley AJ, Paterson HF, Johnston CL, Diekmann D, Hall A (1992) The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell 70:401–410.CrossRefPubMedGoogle Scholar
  54. Rochlitz CF, Scott GK, Dodson JM, et al (1989) Incidence of activating ras oncogene mutations associated with primary and metastatic human breast cancer. Cancer Res 49:357–360.PubMedGoogle Scholar
  55. Rodenhuis S (1992) ras and human tumors. Semin Cancer Biol 3:241–247.PubMedGoogle Scholar
  56. Rose R, Weyand M, Lammers M, Ishizaki T, Ahmadian M, Wittinghofer A (2005) Structural and mechanistic insights into the interaction between Rho and mammalian Dia. Nature 435:513–518.CrossRefPubMedGoogle Scholar
  57. Sahai E, Marshall CJ (2002) ROCK and Dia have opposing effects on adherens junctions downstream of Rho. Nat Cell Biol 4:408–415.CrossRefPubMedGoogle Scholar
  58. Sander EE, ten Klooster JP, van Delft S, van der Kammen RA, Collard JG (1999) Rac downregulates Rho activity: reciprocal balance between both GTPases determines cellular morphology and migratory behavior. J Cell Biol 147:1009–1022.CrossRefPubMedGoogle Scholar
  59. Schwering I, Brauninger A, Distler V, et al (2003) Profiling of Hodgkin’s lymphoma cell line L1236 and germinal center B cells: identification of Hodgkin’s lymphoma-specific genes. Mol Med 9:85–95.PubMedGoogle Scholar
  60. Sequeira L, Dubyk C, Riesenberger T, Cooper CR, van Golen KL (2008) Rho GTPases in PC-3 prostate cancer cell morphology, invasion and tumor cell diapadesis. Clin Exp Metastasis 25(5): 569–579.CrossRefPubMedGoogle Scholar
  61. Shikada Y, Yoshino I, Okamoto T, et al (2003) Higher expression of RhoC is related to invasiveness in non-small cell lung carcinoma. Clin Cancer Res 9:5282–5286.PubMedGoogle Scholar
  62. Shinto E, Tsuda H, Matsubara O, Mochizuki H (2003) [Significance of RhoC expression in terms of invasion and metastasis of colorectal cancer]. Nippon Rinsho 61(Suppl 7):215–219.PubMedGoogle Scholar
  63. Simpson KJ, Dugan AS, Mercurio AM (2004) Functional analysis of the contribution of RhoA and RhoC GTPases to invasive breast carcinoma. Cancer Res 64:8694–8701.CrossRefPubMedGoogle Scholar
  64. Stacey DW, Kung HF (1984) Transformation of NIH 3T3 cells by microinjection of Ha-ras p21 protein. Nature 310:508–511.CrossRefPubMedGoogle Scholar
  65. Suwa H, Yoshimura T, Yamaguchi N, et al (1994) K-ras and p53 alterations in genomic DNA and transcripts of human pancreatic adenocarcinoma cell lines. Jpn J Cancer Res 85:1005–1014.PubMedGoogle Scholar
  66. Takai Y, Sasaki T, Matozaki T (2001) Small GTP-binding proteins. Physiol Rev 81:153–208.PubMedGoogle Scholar
  67. Thalmann GN, Sikes RA, Wu TT, et al (2000) LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis. Prostate 44:91–103.CrossRefPubMedGoogle Scholar
  68. van Golen KL (2003) Inflammatory breast cancer: relationship between growth factor signaling and motility in aggressive cancers. Breast Cancer Research 5:174.CrossRefPubMedGoogle Scholar
  69. van Golen KL, Bao L, DiVito MM, et al (2002a) Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor. Mol. Cancer Ther 1:575–583.Google Scholar
  70. van Golen KL, Bao LW, Pan Q, Miller FR, Wu ZF, Merajver SD (2002b) Mitogen activated protein kinase pathway is involved in RhoC GTPase induced motility, invasion and angiogenesis in inflammatory breast cancer. Clin Exp Metastasis 19:301–311.CrossRefPubMedGoogle Scholar
  71. van Golen KL, Davies S, Wu ZF, et al (1999) A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res 5:2511–2519.PubMedGoogle Scholar
  72. van Golen KL, Wu ZF, Qiao XT, Bao L, Merajver SD (2000a) RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells. Neoplasia 2:418–425.CrossRefPubMedGoogle Scholar
  73. van Golen KL, Wu ZF, Qiao XT, Bao LW, Merajver SD (2000b) RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res 60:5832–5838.PubMedGoogle Scholar
  74. Van Laere S, Van der Auwer I, Van den Eynden GG, Fox SB, Bianchi F, Harris AL, van Dam P, Van Marck EA, Vermuelen PB and Dirix LY Nuclear factor kappa B signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry and nuclear factor kappaB DNA-binding. Breast Cancer Res Treat. (2005) 93(3):237–246.PubMedGoogle Scholar
  75. Wei Y, Zhang Y, Derewenda U, et al (1997) Crystal Structure of RhoA-GDP and its functional implications. Nat Struct Biol 4:699–703.CrossRefPubMedGoogle Scholar
  76. Wu M, Wu ZF, Kumar-Sinha C, Chinnaiyan A, Merajver SD (2004) RhoC induces differential expression of genes involved in invasion and metastasis in MCF10A breast cells. Breast Cancer Res Treat 84:3–12.CrossRefPubMedGoogle Scholar
  77. Yao H, Dashner E, van Golen CM, van Golen KL (2006) RhoC GTPase is required for PC-3 Prostate Cancer Cell Invasion but not Motility. Oncogene 25:2285–2296. Ref Type: AbstractCrossRefPubMedGoogle Scholar
  78. Zhang X, Lin M, van Golen KL, Itoh K, Yee D (2005) Multiple signaling pathways are activated during insulin-like growth factor-I (IGF-1) stimulated breast cancer cell migration. Breast Cancer Res Treat 93:159–168.CrossRefPubMedGoogle Scholar
  79. Zondag GC, Evers EE, ten Klooster JP, Janssen L, van der Kammen RA, Collard JG (2000) Oncogenic Ras downregulates Rac activity, which leads to increased Rho activity and epithelial-mesenchymal transition. J Cell Biol 149:775–782.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Center for Translational Cancer Research, Department of Biological Sciences, Laboratory of Cytoskeletal PhysiologyUniversity of DelawareNewarkUSA

Personalised recommendations